Designed with a smart hour design for the blind and the blind. In the next steps, this technology will be more complete and more information available to the patient ...
By Ben Shaberman on March 20, 2017 A 29-year-old British man is the first person to be treated in a gene therapy clinical trial for X-linked retinitis pigmentosa (XLRP). Robert MacLaren, MD, the lead investigator for the trial taking place at the Oxford Eye Hospital in the United Kingdom, says the patient is doing well [...]
By Dr. Steve Rose on April 4, 2017 USH2A is a target for retinal-disease researchers, because mutations in the gene are the most common cause of Usher syndrome type 2, which causes combined vision loss from retinitis pigmentosa (RP) and hearing loss from inner ear dysfunction. Also, USH2A mutations are a leading cause of RP [...]
By Ben Shaberman on April 28, 2017 The stem-cell therapy company jCyte is launching a Phase IIb clinical trial of its therapy for people with retinitis pigmentosa (RP). The trial is taking place at University of California, Irvine, and Retina-Vitreous Associates Medical Group in Los Angeles. The 70-participant study is being led by Henry Klassen, [...]
[ecwd id="10902" type="full" page_items="5" event_search="yes" display="full" displays="full,list,week,day" filters=""]
Goals and Vision In the eight articles of association of eye disease RP support the goals of the organization specified in paragraph 6: 1- . Low vision and blindness in the country to avoid raising awareness and increasing public awareness 2. The promotion of individual and social life impaired by soliciting the support of the [...]